A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES. SECOND SINGLE-PATIENT CLINICAL TRIAL AT CHU SAINTE-JUSTINE.

Registry ID

EBV-TCL-01-SP2-SJ

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

CHU SAINTE JUSTINE

Last update

2020-04-16

Conditions

• EPSTEIN-BARR VIRUS (EBV) INFECTION
• EPSTEIN-BARR VIRUS-RELATED LYMPHOPROLIFERATIVE DISEASES

Related clinical trials

• A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

View on source registry